Shares of Corcept Therapeutics fell 16% in pre-market trading on January 30, after a report highlighted language in the company’s Complete Response Letter indicating that the FDA had raised concerns during pre-submission meetings and warned the company to expect significant review issues if it proceeded with its relacorilant application. Shares of Corcept fell more than 50% on December 31, 2025, after the company disclosed it had received the CRL, which stated that the agency could not reach a favorable risk-benefit assessment without additional evidence of effectiveness. Block & Leviton LLP is investigating.
Contact our attorneys for a no-cost case evaluation.